Advanced
Trials portfolio
ABC-07
Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers
ABC-07 is a multicentre phase II trial, with a 2:1 randomisation between 6 cycles of cisplatin and gemcitabine (CisGem) chemotherapy followed by Stereotactic Body Radiotherapy (SBRT), and 8 cycles Cis [...]
Area: Upper gastro-intestinal cancer
Phase: Phase II
Status: Active (recruiting)
ALLCAR19
Immunotherapy for high risk/relapsed CD19+ Acute Lymphoblastic Leukaemia using CAR T-cells to target CD19
ALLCAR19 is a multi-site, non-randomised phase I trial in adults with high risk or refractory CD19+ B-cell Acute Lymphoblastic Leukaemia. The Advanced Therapy Investigational Medicinal Product (ATIMP) [...]
Area: Advanced therapies
Phase: Phase I
Status: Active (recruiting)
ANIMATE
A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first or second line salvage therapy
Single-arm, open label, multicentre phase IItrial.
Area: Haematological cancer
Phase: Phase II
Status: Active (recruiting)
ARISTOTLE
A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer
ARISTOTLE is a multicentre, phase III, randomised trial comparing standard neoadjuvant chemoradiotherapy (CRT) of oral capecitabine and radiotherapy versus standard CRT with the addition of irinotecan [...]
Area: Lower gastro-intestinal cancer
Phase: Phase III
Status: In follow-up (non-recruiting)
AVENuE
Avelumab in the frontline treatment of advanced classical Hodgkin lymphoma - a window study
AVENuE is a non-randomised, single arm Phase II trial investigating how patients with newly diagnosed, untreated advanced classical Hodgkin lymphoma respond to treatment with the monocolonal antibody, [...]
Area: Haematological cancer
Phase: Phase II
Status: In set-up (funded)
BACCHUS
A phase II Multicentre Open-label Randomised Study of Neoadjuvant Chemotherapy and Bevacizumab in Patients with MRI defined High-Risk Cancer of the Rectum
A Phase II, Multicentre, Open-label, Randomised Study of Neoadjuvant Chemotherapy and Bevacizumab in Patients with MRI defined High-Risk Cancer of the Rectum.
Area: Lower gastro-intestinal cancer
Phase: Phase II
Status:
BCT
PHASE II STUDY OF BORTEZOMIB CONSOLIDATION AFTER HIGH DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA
BCT is a non-randomised, single arm, multicentre, phase II trial of bortezomib consolidation after high dose therapy (HDT) and autologous stem cell transplantation (ASCT) for patients with multiple my [...]
Area: Haematological cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
CARD
CAR19 Donor Lymphocytes for relapsed CD19+ malignancies following allogeneic transplantation
CARD is a single centre, single arm intra-patient dose-escalation phase I study in adults with relapsed CD19+ malignancies following allogeneic stem cell transplantation. The Advanced Therapies Invest [...]
Area: Advanced therapies
Phase: Phase I
Status: Active (recruiting)
Cardamon
Carfilzomib/Cyclophosphamide/Dexamethasone with maintenance carfilzomib in untreated transplant-eligible patients with symptomatic MM to evaluate the benefit of upfront ASCT
Cardamon is a randomised (1:1), multicentre, phase II trial of carfilzomib, cyclophosphamide and dexamethasone (CarCyDex) as induction in untreated patients with symptomatic multiple myeloma who are c [...]
Area: Haematological cancer
Phase: Phase II
Status: Active (recruiting)
CARPALL
Immunotherapy with CD19 CAR redirected T-cells for high risk/relapsed paediatric CD19+ acute lymphoblastic leukaemia and other haematological malignancies
A multi-centre, non-randomised, open label phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and young adults with high risk, relapsed CD19+ haematolo [...]
Area: Advanced therapies
Phase: Phase I
Status: Active (recruiting)
CD-19TPALL
Immunotherapy with CD19? gene modified EBV-specific CTLs after stem cell transplant in children with high-risk acute lymphoblastic leukaemia
a multi-site, non-randomised, phase I/II, paediatric trial with 2 arms. The Advanced Therapy Medicinal product (ATMP) tested in the study is donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) tran [...]
Area: Advanced therapies
Phase: Phase I/II
Status: Closed
COBALT
Evaluation of CAR19 T-cells as an optimal bridge to allogeneic transplantation.
Single centre, single arm dose-escalation phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults with resistant or relapsed DLBCL. The ATIMP tested in this s [...]
Area: Advanced therapies
Phase: Phase I
Status: Active (recruiting)
CORAL
Randomised study of ICE + Rituximab (R-ICE) versus DHAP Rituximab (R-DHAP) in previously treated patients with CD20 positive diffuse large B-cell Non-Hodgkins lymphoma, eligible for high dose chemotherapy followed by randomised maintenance treatment with Rituximab
CORAL is a multicentre, phase III open-label, randomized trial evaluating the efficacy of R-ICE compared to R-DHAP with previously treated diffuse large B-cell lymphoma, followed by high-dose chemothe [...]
Area: Haematological cancer
Phase: Phase III
Status: Closed
DARWIN 1
Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity
DARWIN1 is an open label, multi-centre single arm phase II trial for eligible patients who relapse whilst taking part in the TRACERx study.
Area: Lung cancer
Phase: Phase II
Status: Active (recruiting)
DARWIN 2
Deciphering Anti-tumour Response and Resistance With INtratumour Heterogeneity
DARWIN II is a phase II multi-centre non-randomised trial for NSCLC patients to study tumour heterogeneity using genomic analysis. The trial will only be opened in sites participating in the TRACERx s [...]
Area: Lung cancer
Phase: Phase II
Status: Active (recruiting)
EACH
Evaluating Avelumab in combination with Cetuximab in Head and neck cancer
EACH is a randomised phase II trial preceded by a safety run-in phase. The safety run-in will be of a single arm de-escalating design which will recruit up to 16 patients with a variety of recurrent a [...]
Area: Head & neck cancer
Phase: Phase II
Status: Active (recruiting)
EARL
Electrocautery Ablation for the Prevention of Lung Cancer
EARL is a phase II/III multicentre 2:1 randomised controlled trial to evaluate the effectiveness of electrocautery (EC) in the treatment of high-grade lesions of the lung. All patients consented/regis [...]
Area: Lung cancer
Phase: Phase II/III
Status: In set-up (funded)
EXCITE
Erbitux, Xeloda, Campto, Irradiation Then Excision for locally advanced rectal cancer (North West/North Wales Clinical Oncology Group-04 on behalf of the NCRI rectal cancer subgroup)
Area: Lower gastro-intestinal cancer
Phase: Phase II
Status:
GALA-5 Long Term Follow Up
Long term follow up of patients in the GALA5 trial: an Evaluation of the Tolerability and Feasibility of combining 5-Amino-Levulinic Acid (5ALA) with Carmustine Wafers (Gliadel) in the Surgical Management of Primary Glioblastoma
The GALA-5 trial was a single arm feasibility study to evaluate the safety and tolerability of combining 2 technologies (5-ALA and Carmustine wafers) in the surgical management of patients with gliobl [...]
Area: Brain cancer
Phase: Observational trials
Status: In follow-up (non-recruiting)
GeDDiS
A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas.
GeDDiS was a randomised, phase III multinational trial, with patients stratified according to age (≤18 or >18) and histological subtype (uterine leiomyosarcoma, synovial sarcoma, pleomorphic sarcoma, [...]
Area: Sarcoma
Phase: Phase III
Status: In follow-up (non-recruiting)
HCQ
A randomised phase 2 trial investigating the additional benefit of hydroxychloroquine (HCQ) to short course radiotherapy (SCRT) in patients aged 70 years and older with high grade gliomas (HGG)
HCQ is a randomised (2:1), multicentre, phase II study comparing hydroxychloroquine (HCQ) and short course radiotherapy (SCRT) with SCRT alone to examine the effect on one-year survival in patients ag [...]
Area: Brain cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
HiLo
Multicentre randomised trial of high dose versus low dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation following surgery for differentiated thyroid cancer.
HiLo was a randomised, phase III factorial randomised trial, stratified according to trial site, T stage and N stage.
Area: Head & neck cancer
Phase: Phase III
Status: In follow-up (non-recruiting)
HIPPO
A randomized phase II trial of Hippocampal Sparing versus Conventional Whole Brain Radiotherapy after surgical resection or radiosurgery in favourable prognosis patients with 1-4 brain metastases
HIPPO is a 1:1 randomised multicentre phase II study investigating Hippocampal Sparing Whole Brain Radiotherapy (HS-WBRT) versus standard Whole Brain Radiotherapy (WBRT) after neurosurgery or stereota [...]
Area: Brain cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
HOVON 127 Burkitt Lymphoma
Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma
HOVON 127 BL is a randomized, open-label, prospective, multicentre phase III study. All eligible patients will be randomized to receive either R-CODOX-M/R-IVAC or DA-EPOCH-R.
Area: Haematological cancer
Phase: Phase III
Status: In set-up (funded)
ICAT
Adoptive Immunotherapy with CD25/71 allodepleted donor T cells to improve immunity after unrelated donor stem cell transplant.
ICAT is a multi-centre randomised phase II trial in adult patients with an underlying haematological malignancy undergoing unrelated donor peripheral blood stem cell transplant with Alemtuzumab-based [...]
Area: Advanced therapies
Phase: Phase II
Status: Active (recruiting)
ICON9
An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
ICON9 is an international phase III randomised study to evaluate the efficacy of maintenance olaparib and cediranib combination therapy or olaparib alone in patients with relapsed platinum-sensitive o [...]
Area: Gynaecological cancer
Phase: Phase III
Status: Active (recruiting)
IDEAL-CRT
A phase I/II trial of concurrent chemoradiation with dose-escalated radiotherapy in patients with stage II or stage III Non-Small Cell Lung Cancer
IDEAL-CRT is a multicentre phase I/II trial of concurrent chemoradiation with dose-escalated radiotherapy in patients with stage II or stage III Non-Small Cell Lung Cancer.
Area: Lung cancer
Phase: Phase I/II
Status: Closed
IDRIS
Phase III randomised trial of immunomodulatory therapy in high risk solitary bone plasmacytoma
IDRIS is a multicentre randomised phase III study investigating whether a combination of lenalidomide and dexamethasone can delay or prevent disease progression in patients with newly-diagnosed solita [...]
Area: Haematological cancer
Phase: Phase III
Status: Active (recruiting)
IMRiS
A phase II study of intensity modulated radiotherapy (IMRT) in primary bone and soft tissue sarcoma
This is a prospective multicentre phase II trial of intensity modulated radiotherapy (IMRT) in patients with bone or soft tissue sarcoma, split into 3 cohorts
Area: Sarcoma
Phase: Phase II
Status: Active (recruiting)
INCA
A multicentre randomised phase II clinical trial of Inotuzumab Ozogamicin (INO) plus Rituximab and CVP (IO-R-CVP) versus Gemcitabine plus Rituximab and CVP (Gem-R-CVP) for the first line treatment of patients with Diffuse Large B Cell Lymphoma (DLBCL) who
INCA is a multicentre, randomised, phase II trial comparing IO-R-CVP with Gem-R-CVP in the first line treatment of patients with DLBCL who are not fit for anthracycline-containing chemotherapy.
Area: Haematological cancer
Phase: Phase II
Status: Active (recruiting)
INTERLACE
A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation vs standard chemoradioation alone in patients with locally advanced cervical cancer
INTERLACE is a phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer.
Area: Gynaecological cancer
Phase: Phase III
Status: Active (recruiting)
IoN
Is ablative radiOiodine Necessary for low risk patients.
IoN is a randomised, non-blind, non-inferiority phase III multicentre trial, randomised using the minimisation method and stratified according to site, patient age, T Stage and N Stage to decide if pa [...]
Area: Head & neck cancer
Phase: Phase II/III
Status: Active (recruiting)
ITREC
Immunotherapy with Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease after Solid Organ Transplant
ITREC is a multi-site, non-randomised phase I trial in children and adults with Post Transplant Lymphoproliferative Disease (PTLD) after solid organ transplant. The Advanced Therapy Investigational Me [...]
Area: Advanced therapies
Phase: Phase I
Status: Active (recruiting)
Lung Trans
Biomarker Analysis to Predict Response in Lung Cancer
Lung Trans is a non-interventional laboratory study.
Area: Lung cancer
Phase: Laboratory study
Status: In set-up (funded)
MCL MiniAllo
Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma
MCL MiniAllo is a single arm, non−randomised phase II study investigating the use of reduced intensity allogeneic stem cell transplantation for mantle cell lymphoma in first remission.
Area: Haematological cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
MESO-02
A phase I/II study of first line ganetespib with pemetrexed/Cisplatin in patients with malignant pleural mesothelioma
A phase I/II study of first line ganetespib with pemetrexed-platinum in patients with malignant pleural mesothelioma. Phase I follows a 3+3 dose escalation design (cisplatin patients) and an accelerat [...]
Area: Lung cancer
Phase: Phase I/II
Status: In follow-up (non-recruiting)
METRO-BIBF
Phase II, randomised, placebo controlled, multicentre, feasibility study of low dose (metronomic) cyclophosphamide with or without nintedanib (BIBF1120) in advanced ovarian cancer (METRO–BIBF)
METRO-BIBF is a phase II, randomised, placebo-controlled, multi-centre, feasibility study of low dose (metronomic) cyclophosphamide with and without nintedanib (BIBF 1120) in advanced ovarian cancer.
Area: Gynaecological cancer
Phase: Phase II
Status: Closed
NEPTUNES
Nivolumab and Ipilimumab treatment in prostate cancer with an immunogenic signature
NEPTUNES is a single arm, multicentre phase II study for patients with metastatic prostate adenocarcinoma which has not responded to 1st line treatments with androgen blockage.There are 2 stages.The f [...]
Area: Prostate cancer
Phase: Phase II
Status: Active (recruiting)
ORCA-2
ORCA-2: a phase I study of olaparib in addition to cisplatin based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck (NHSCC).
ORCA-2 is a phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck (HNSCC). The [...]
Area: Head & neck cancer
Phase: Phase I
Status: Active (recruiting)
PADIMAC
Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT.
PADIMAC is non-randomised, single arm, multicentre phase II trial evaluating the safety of multiple myeloma patients that have achieved a Complete Response (CR) or Very Good Partial Response (VGPR) po [...]
Area: Haematological cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
PAIReD
Phase II study of reduced intensity allogeneic transplantation for refractory Hodgkin lymphoma
PAIReD is a multicentre phase II single-arm trial of BEAM-Campath conditioned reduced intensity stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma.
Area: Haematological cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
PANTHER
AZD8931, an EGFR inhibitor, in combination with FOLFIRI: A Phase I/II study to determine the importance of schedule and activity in colorectal cancer
PANTHER is a phase I/II trial in patients with recurrent or metastatic colorectal cancer. Phase I has closed to recruitment. The phase II part of the study is a single arm trial of AZD8931 + FOLFIRI.
Area: Lower gastro-intestinal cancer
Phase: Phase I/II
Status: In follow-up (non-recruiting)
PEACE
The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study
Posthumous Evaluation of Advanced Cancer Environment Study is a multi-centre prospective observational study
Area: Lung cancer
Phase: Tissue collection
Status: Active (recruiting)
PEACOCC
A phase II study of pembrolizumab in patients with advanced gynaecological clear cell cancer
PEACOCC is a phase II, single Arm, UK multi-centre study. All patients will receive the same dose of Pembrolizumab. All eligible patients will have advanced gynecological clear cell cancer upon trial [...]
Area: Gynaecological cancer
Phase: Phase II
Status: Active (recruiting)
PembroWM
A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström’s macroglobulinaemia
A phase II, non-randomised, single arm, open-label trial.
Area: Haematological cancer
Phase: Phase II
Status: In set-up (funded)
PETROC
A Phase II/III study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus IV carboplatin plus paclitaxel in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy (PETROC/OV21)
This is an international randomised, non-blinded multicentre phase II Gynecologic Cancer Intergroup trial coordinated by the NCIC Clinical Trials Group in conjunction with SWOG (US), the Cancer Resear [...]
Area: Gynaecological cancer
Phase: Phase II
Status: Closed
PORT
Phase II Trial of Pembrolizumab and Radiotherapy in Cutaneous T cell lymphoma
PORT is a multicentre, single arm, phase II trial of pembrolizumab in combination with radiotherapy for patients with relapsed/refractory CTCL.
Area: Haematological cancer
Phase: Phase II
Status: Active (recruiting)
PORTEC-3
Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma
PORTEC-3 is a prospective, multicentre, randomised Phase III intergroup trial led by the Dutch Cooperative Gynaecologic Oncology Group, in collaboration with the UK National Cancer Research Institute, [...]
Area: Gynaecological cancer
Phase: Phase III
Status: In follow-up (non-recruiting)
PRIMA
A multicentre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera®) after induction of response with chemotherapy plus Rituximab in comparison with no maintenance therapy
PRIMA is an open label, international, multicentre, randomiszed study with two treatment phases. During the first phase, patients will be evaluated for response to different induction regimens. In the [...]
Area: Haematological cancer
Phase: Phase III
Status: Closed
ProT4
Multicentre randomised phase II study to evaluate the efficacy of prophylactic transfer of CD4 lymphocytes after T-cell depleted reduced intensity HLA-identical sibling transplantation for haematological cancers
ProT4 is a multicentre, randomised phase II trial to evaluate the efficacy of prophylactic transfer of donor CD4 lymphocytes after T-cell depleted reduced intensity allogeneic transplantation for haem [...]
Area: Haematological cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
R2W
Randomised phase 2 trial in WM - Subcutaneous Bortezomib, Clycophosphamide and Rituximab (BCR versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for initial therapy of Waldenstr?m’s macroglobulinaemia (WM): a randomised phase II trial
R2W is a randomised (2:1), non-comparative, multicentre, phase II trial of bortezomib, cyclophosphamide and rituximab (BCR – experimental) versus fludarabine, cyclophosphamide and rituximab (FCR – con [...]
Area: Haematological cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
RAPID
A Randomised Phase III Trial to Determine the Role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin’s Disease
A randomised (1:1), multicentre, phase III trial to determine whether patients with clinical stage IA/IIA Hodgkin’s disease who have a negative FDG-PET scan after 3 cycles of ABVD require consolidatio [...]
Area: Haematological cancer
Phase: Phase III
Status: In follow-up (non-recruiting)
RATHL
A randomised Phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin Lymphoma
RATHL is a multi-centre randomised trial comparing treatment outcome for patients with advanced Hodgkin lymphoma, using FDG-PET imaging after 2 cycles of ABVD to determine response and subsequent mana [...]
Area: Haematological cancer
Phase: Phase III
Status: In follow-up (non-recruiting)
R-CHOP 14 vs 21
A phase III multicentre randomised clinical trial comparing rituximab with CHOP given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin’s lymphoma.
A multicentre randomised trial comparing R-CHOP 14 given for 6 cycles with R-CHOP 21 given for 8 cycles in patients with newly diagnosed CD20 positive diffuse large B cell lymphoma, bulky stage IA to [...]
Area: Haematological cancer
Phase: Phase III
Status: Closed
ReBeL
ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients >= 18 years with relapsed follicular lymphoma. A HOVON/GLSG/NCRI study
ReBeL is a prospective, randomised, multicentre, international phase II trial (phase I is not being conducted in the UK). ReBeL has two experimental arms; lenalidomide and rituximab versus lenalidomid [...]
Area: Haematological cancer
Phase: Phase II
Status: Active (recruiting)
RETRO-CHOP
A retrospective translational study: Characterisation of molecular predictors of outcome in patients with diffuse large B cell lymphoma treated on the R-CHOP14 vs 21 multicentre trial
This is a retrospective study which aims to perform biomarker analyses on archived samples from patients with diffuse large B cell lymphoma (DLBCL) who have been treated on the R-CHOP 14 vs 21 multice [...]
Area: Haematological cancer
Phase: Tissue collection
Status: Active (recruiting)
RIC UCBT
Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients with Haematological Diseases using a Reduced Intensity Conditioning Regimen
RIC-UCBT is a multicentre phase II single-arm trial of reduced-intensity conditioned umbilical cord blood transplantation in patients with haematological diseases.
Area: Haematological cancer
Phase: Phase II
Status: Closed
SARON
Stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer. A randomised phase III trial
SARON is a randomised, controlled phase III trial of chemotherapy versus chemotherapy + radiotherapy in patients with oligometastatic (1-3 metastases) non-small cell lung cancer (NSCLC) patients. Sub [...]
Area: Lung cancer
Phase: Phase III
Status: Active (recruiting)
SCORAD III
A randomised phase III trial of single fraction radiotherapy compared to multifraction radiotherapy in patients with metastatic spinal cord compression (SCC).
SCORAD III was a multicentre, randomised phase III trial, stratified according to radiotherapy centre, ambulatory status, type of primary tumour and extent of disease (presence or absence of nonskelet [...]
Area: Bone Mets
Phase: Phase III
Status: Closed
SHAPE
A randomised phase III trial comparing radical hysterectomy and pelvic node dissection vs simple hysterectomy and pelvic node dissection in patients with low-risk early-stage cervical cancer
SHAPE is a multi-centre, international, prospective, randomised phase III trial of radical hysterectomy and pelvic node dissection versus simple hysterectomy and pelvic node dissection in patients wit [...]
Area: Gynaecological cancer
Phase: Phase III
Status: Active (recruiting)
STATEC
A randomised trial of non-Selective versus selective adjuvant Therapy in high risk Apparent sTage 1 Endometrial Cancer
STATEC is a randomised (1:1) multicentre international phase III trial of hysterectomy with lymphadenectomy vs hysterectomy alone in women with high risk apparent stage I endometrial cancer.
Area: Gynaecological cancer
Phase: Phase III
Status: Recruitment suspended
Streamline-C
Streamlining staging of colorectal cancer with Whole Body MRI
Multicentre comparison
Area: Lower gastro-intestinal cancer
Phase: Observational trials
Status: In follow-up (non-recruiting)
Streamline-L
Streamlining staging of lung cancer with Whole Body MRI
Multicentre comparison
Area: Lower gastro-intestinal cancer
Phase: Observational trials
Status: In follow-up (non-recruiting)
Study 15
A multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychlroquine with carboplatin/etoposide therapy in extensive stage small cell lung cancer (SCLC)
Study 15 is a multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychloroquine (HCQ) versus carboplatin/etoposide therapy alone in small cell lung cancer.
Area: Lung cancer
Phase: Phase II
Status: Active (recruiting)
TACTICAL
Targeted stromal cells expressing TRAIL as a therapy for lung cancer
Phase I:Single site dose de-escalation design with a modified Bayesian continual reassessment method (mCRM) to estimate the recommended Phase II dose (RP2D) of MSCTRAIL in combination with pemetrexed/ [...]
Area: Advanced therapies
Phase: Phase I/II
Status: Active (recruiting)
TIMELY
Trial of afatinib in suspected or confirmed mutant EGFR lung cancer patients unfit for chemotherapy
TIMELY is an open label single arm phase II trial using an irreversible second generation EGFR inhibitor, afatinib. Trial afatinib treatment is given to non-small cell lung cancer (NSCLC) patients who [...]
Area: Lung cancer
Phase: Phase II
Status: Closed
TRACERx
TRAcking non small cell lung Cancer Evolution through therapy (Rx)
TRACERx is a prospective observational cohort study of patients with non-small cell lung cancer (NSCLC), in which translational research is the fundamental aspect of the study.
Area: Lung cancer
Phase: Observational trials
Status: Active (recruiting)
Triangle
Autologous transplantation after a rituximab/ ibrutinib/ Ara-C containing induction in generalized mantle cell lymphoma – a randomized European MCL network trial.
Triangle is a randomized, three-arm, parallel-group, open label international phase III trial.
Area: Haematological cancer
Phase: Phase III
Status: In set-up (funded)
TRIOC
A phase II study to assess the activity of TroVax (MVA-5T4) versus placebo in patients with relapsed asymptomatic epithelial ovarian, fallopian tube or primary peritoneal cancer
TRIOC is a prospective multicentre phase II trial in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer who develop asymptomatic relapse as confirmed by either elevated CA-1 [...]
Area: Gynaecological cancer
Phase: Phase II
Status: Closed
UKALL14
A randomised trial for adults with newly diagnosed acute lymphoblastic leukaemia
UKALL14 is a Phase III multicentre randomised trial for adults with newly-diagnosed Acute Lymphoblastic Leukaemia (ALL). The main randomisations investigate standard induction chemotherapy with or wit [...]
Area: Haematological cancer
Phase: Phase III
Status: Active (recruiting)
UKALL60
A Phase 2 study for older adults with Acute Lymphoblastic Leukaemia
UKALL60+ is a multicentre, non-randomised Phase II trial forolder patients with Acute Lymphoblastic Leukaemia (ALL). There are four treatment pathways based on standard practice here in the UK and in [...]
Area: Haematological cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
UK-Haplo
UK-Haplo: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies
UK Haplo is a multicentre, non-randomised Phase II trial in patients with haematological malignancies to investigate whether it is possible to carry out haploidentical peripheral blood stem cell trans [...]
Area: Haematological cancer
Phase: Phase II
Status: Active (recruiting)
VEROnA
A pilot, open label, single-arm, phase 0, window of opportunity study of vandetanib-eluting radiopaque embolic beads (BTG-002814) in patients with resectable liver malignancies
VEROnA is a pilot, open label, single arm, Phase 0 window of opportunity study of vandetanib eluting radiopaque embolic beads.
Area: Upper gastro-intestinal cancer
Phase: Phase 0
Status: Active (recruiting)
Watch & Wait
An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma (Grades 1, 2 and 3a)
The Watch and Wait study is a randomised phase III trial to determine whether giving treatment with rituximab to patients with advanced stage asymptomatic follicular lymphoma (grades 1, 2 and 3a) resu [...]
Area: Haematological cancer
Phase: Phase III
Status: In follow-up (non-recruiting)
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2019 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us